

TNAP (F-4): sc-166261

BACKGROUND

Alkaline phosphatases (AP) are glycosyl-phosphatidylinositol (GPI)-anchored, dimeric, Zn²⁺ metallated glycoproteins that catalyze the hydrolysis of phospho-monoesters into an inorganic phosphate and an alcohol. There are at least four distinct but related alkaline phosphatases: intestinal (IAP), placental (PLAP), placental-like (ALP-1 or GCAP) and tissue non-specific (TNAP). The first three are located together on chromosome 2 while the tissue non-specific form is located on chromosome 1. TNAP is widely expressed in liver, kidney, bone, stomach and colon, and is therefore referred to as the tissue non-specific form of AP. TNAP, in conjunction with plasma cell membrane glycoprotein-1, function in bone mineralization; however, mice that lack a functional form of TNAP show normal skeletal development. This enzyme has been linked directly to a disorder known as hypophosphatasia, a rare inborn disorder that is characterized by defective bone mineralization and includes skeletal defects. Human gene encoding TNAP maps to chromosome 1p36.12.

CHROMOSOMAL LOCATION

Genetic locus: ALPL (human) mapping to 1p36.12; Alpl (mouse) mapping to 4 D3.

SOURCE

TNAP (F-4) is a mouse monoclonal antibody raised against amino acids 18-317 mapping near the N-terminus of TNAP of human origin.

PRODUCT

Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

TNAP (F-4) is available conjugated to agarose (sc-166261 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-166261 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-166261 PE), fluorescein (sc-166261 FITC), Alexa Fluor® 488 (sc-166261 AF488), Alexa Fluor® 546 (sc-166261 AF546), Alexa Fluor® 594 (sc-166261 AF594) or Alexa Fluor® 647 (sc-166261 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-166261 AF680) or Alexa Fluor® 790 (sc-166261 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

TNAP (F-4) is recommended for detection of TNAP of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


Suitable for use as control antibody for TNAP siRNA (h): sc-38921, TNAP siRNA (m): sc-38922, TNAP shRNA Plasmid (h): sc-38921-SH, TNAP shRNA Plasmid (m): sc-38922-SH, TNAP shRNA (h) Lentiviral Particles: sc-38921-V and TNAP shRNA (m) Lentiviral Particles: sc-38922-V.

Molecular Weight of TNAP/PLAP/GCAP/IAP: 80/70/23/57 kDa.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



TNAP (F-4): sc-166261. Western blot analysis of TNAP expression in HeLa (A), MCF7 (B) and Saos-2 (C) whole cell lysates. Detection reagent used: m-IgGκ-BP-HRP: sc-516102.



TNAP (F-4): sc-166261. Immunoperoxidase staining of formalin fixed, paraffin-embedded human adrenal gland tissue showing membrane and cytoplasmic staining of glandular cells.

SELECT PRODUCT CITATIONS

- James, A.W., et al. 2014. Lentiviral delivery of PPAR γ shRNA alters the balance of osteogenesis and adipogenesis, improving bone microarchitecture. *Tissue Eng. Part A* 20: 2699-2710.
- Schira, J., et al. 2015. Human scaphoid non-unions exhibit increased osteoclast activity compared to adjacent cancellous bone. *J. Cell. Mol. Med.* 19: 2842-2850.
- Muerza-Cascante, M.L., et al. 2016. Endosteal-like extracellular matrix expression on melt electrospun written scaffolds. *Acta Biomater.* 52: 145-158.
- Wallner, C., et al. 2017. Inhibition of GDF8 (myostatin) accelerates bone regeneration in diabetes mellitus type 2. *Sci. Rep.* 7: 9878.
- Campsie, P., et al. 2019. Design, construction and characterisation of a novel nanovibrational bioreactor and cultureware for osteogenesis. *Sci. Rep.* 9: 12944.
- Suzuki, E., et al. 2020. Detailed analyses of the crucial functions of Zn transporter proteins in alkaline phosphatase activation. *J. Biol. Chem.* 295: 5669-5684.
- Bagne, L., et al. 2021. Electrical therapies act on the Ca²⁺/CaM signaling pathway to enhance bone regeneration with bioactive glass [S53P4] and allogeneic grafts. *J. Biomed. Mater. Res. B, Appl. Biomater.* 109: 2104-2116.
- Ueda, S., et al. 2022. Early secretory pathway-resident Zn transporter proteins contribute to cellular sphingolipid metabolism through activation of sphingomyelin phosphodiesterase 1. *Am. J. Physiol. Cell Physiol.* 322: C948-C959.
- Nishito, Y., et al. 2024. Zinc and manganese homeostasis closely interact in mammalian cells. *FASEB J.* 38: e23605.

RESEARCH USE

For research use only, not for use in diagnostic procedures.